Want to see CVS full AI Analyst Report?
Revenue by Segment
Breaks down sales across different business units, revealing which areas contribute most to growth and where the company might face challenges or opportunities.CVS’s revenue mix is shifting toward Health Care Benefits and Health Services as the primary growth engines—Aetna improvements and Oak Street lift HCB while Caremark’s top line rebounded—yet Pharmacy & Consumer’s revenue gains mask profit stress from reimbursement and seasonality. Increasingly large intersegment eliminations are subtracting from consolidated growth, so headline revenue growth understates underlying segment momentum. Management’s guidance upgrade leans on AOI recovery and cost control at Aetna and HSS, not a return to PCW margin strength.
Date | Corporate and Other | Health Care Benefits | Health Services | Pharmacy and Consumer | Intersegment |
|---|---|---|---|---|---|
Jun 30, 2026 | $147.00M | $37.54B | $51.80B | $33.82B | -$17.20B |
Mar 31, 2026 | $126.00M | $35.97B | $48.24B | $31.99B | -$15.90B |
Dec 31, 2025 | $122.00M | $36.29B | $51.24B | $37.66B | -$19.63B |
Sep 30, 2025 | $133.00M | $35.99B | $49.27B | $36.21B | -$18.73B |
Jun 30, 2025 | $96.00M | $36.26B | $46.45B | $33.58B | -$17.47B |
Mar 31, 2025 | $133.00M | $34.81B | $43.46B | $31.91B | -$15.73B |
Dec 31, 2024 | $83.00M | $32.96B | $47.02B | $33.51B | -$15.87B |
Sep 30, 2024 | $142.00M | $33.00B | $44.13B | $32.42B | -$14.26B |
Jun 30, 2024 | $111.00M | $32.48B | $42.17B | $29.84B | -$13.36B |
Mar 31, 2024 | $115.00M | $32.24B | $40.28B | $28.73B | -$12.92B |